Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells

Oncology Reports

Volumn 12, Issue 6, 2004, Pages 1371-1375

  Issat, Tadeusz ^a   Nowis, Dominika ^a   Jaköbisiak, Marek ^a   Golab, Jakub ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Lovastatin; Lymphona; Protease inhibitors; Saquinavir

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PROTEINASE INHIBITOR; SAQUINAVIR;

ARTICLE; DOSE RESPONSE; DRUG POTENTIATION; HUMAN; LYMPHOMA; TUMOR CELL LINE;

CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HIV PROTEASE INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; LYMPHOMA; SAQUINAVIR;

EID: 16644392871     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.6.1371     Document Type: Article

References (29)

1. Carr A and Cooper DA: Adverse effects of antiretroviral therapy. Lancet 356: 1423-1430, 2000.
2. Manfredi R and Chiodo F: Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect 42: 181-188, 2001. (Pubitemid 32707794)
3. Roberts AD, Muesing RA, Parenti DM, Hsia J, Wasserman AG and Simon GL: Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clin Infect Dis 29: 441-443, 1999. (Pubitemid 29380215)
4. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ and Cooper DA: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-58, 1998. (Pubitemid 28190689)
5. Smith JH, Martin GJ and Decker CF: Hyperlipidemia associated with the use of protease inhibitors. Clin Infect Dis 31: 207-208, 2000. (Pubitemid 32268973)
6. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348: 702-710,2003. (Pubitemid 36237039)
7. Wierzbicki AS, Reynolds TM, Crook MA, Tatler J and Peters BS: Lipid lowering therapy in patients with HIV infection. Lancet 352:1782,1998.
8. Biggar RJ: AIDS-related cancers in the era of highly active antiretroviral therapy. Oncology 15: 439-448, 2001.
9. Pajonk F, Himmelsbach J, Riess K, Sommer A and McBride WH: The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 62: 5230-5235, 2002. (Pubitemid 35024595)
10. Gaedicke S, Firat-Geier E, Constantiniu O, Lucchiari-Hartz M, Freudenberg M, Galanos C and Niedermann G: Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 62: 6901-6908, 2002. (Pubitemid 35424079)
11. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussolino F, Monini P and Ensoli B: HIV protease inhibitors are potent antiangiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 8: 225-232, 2002. (Pubitemid 34250099)
12. Pati S, Pelser CB, Dufraine J, Bryant JL, Reitz MS Jr and Weichold FF: Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 99: 3771-3779, 2002. (Pubitemid 34534550)
13. Jakobisiak M and Golab J: Potential antitumor effects of statins (Review). Int J Oncol 23: 1055-1069, 2003.
14. Giermasz A, Makowski M, Kozlowska E, Nowis D, Maj M, Jalili A, Feleszko W, Wojcik C, Dabrowska A, Jakobisiak M and Golab J: Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. Int J Cancer 97: 746-750, 2002. (Pubitemid 34106327)
15. Makowski M, Grzela T, Niderla J, M LA, Mroz P, Kopee M, Legat M, Strusinska K, Koziak K, Nowis D, Mrowka P, Wasik M, Jakobisiak M and Golab J: Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. Clin Cancer Res 9: 5417-5422, 2003.
16. Golab J, Stoklosa T, Czajka A, Dabrowska A, Jakobisiak M, Zagozdzon R, Wojcik C, Marczak M and Wilk S: Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice. Anticancer Res 20: 1717-1721, 2000. (Pubitemid 30628192)
17. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD and Penn LZ: Blocking protein geranylgeranylation is essential for Iovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 15: 1398-1407, 2001. (Pubitemid 32785309)
18. Matar P, Rozados VR, Binda MM, Roggero EA. Bonfil RD and Scharovsky OG: Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma. Clin Exp Metastasis 17: 19-25, 1999. (Pubitemid 29284560)
19. Ikezoe T, Saito T, Bandobashi K, Yang Y, Koeffler HP and Taguchi H: HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. Mol Cancer Ther 3: 473-479, 2004. (Pubitemid 39193725)
20. Ikezoe T, Daar ES, Hisatake J, Taguchi H and Koeffler HP: HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood 96: 3553-3559, 2000.
21. Washington CB, Duran GE, Man MC, Sikic BI and Blaschke TF: Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotcin (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retroviral 19: 203-209, 1998.
22. Muller-Tidow C, Kiehl M, Sindermann JR, Probst M, Banger N, Zuhlsdorf M, Chou TC, Berdel WE, Serve H and Koch OM: Synergistic growth inhibitory effects of interferon-alpha and lovastatin on bcr-abl positive leukemic cells. Int J Oncol 23: 151-158, 2003.
23. Feleszko W, Jalili A, Olszewska D, Mlynarczuk I, Grzela T, Giermasz A and Jakobisiak M: Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. Oncol Rep 9: 879-885, 2002.
24. Feleszko W, Zagozdzon R, Golab J and Jakobisiak M: Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice. Eur J Cancer 34: 406-411, 1998. (Pubitemid 28183843)
25. Feleszko W, Lasek W, Golab J and Jakobisiak M: Synergistic antitumor activity of tumor necrosis factor-alpha and lovastatin against MmB16 melanoma in mice. Neoplasma 42: 69-74, 1995.
26. Kozar K, Kaminski R, Legat M, Kopec M, Nowis D, Skierski JS, Koronkiewicz M, Jakobisiak M and Golab J: Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int J Oncol 24: 1149-1157, 2004.
27. Fichtenbaum CJ and Gerber JG: Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 41: 1195-1211, 2002. (Pubitemid 35398692)
28. Fujino H, Saito T, Tsunenari Y and Kojima J: Interaction between several medicines and statins. Arzneimittelforschung 53: 145-153, 2003. (Pubitemid 36363609)
29. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B and Aweeka F: Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16: 569-577, 2002. (Pubitemid 34218852)